Refining Prognosis in Advanced Renal Cell Carcinoma: International Real-World Validation of the Meet-URO Score in First-Line Immunotherapy Combinations.
Rebuzzi SE, Ghose A, Rudman S, Venugopal B, Young K, Frazer RD, Ayodele O, Stares M, O'Carrigan B, Ali W, McGrane J, Jain A, Fiala O, Chauhan V, Michael A, Zarkar A, Kapur G, Charnley N, Afshar M, Vengalil S, Forde C, Brown J, Urun Y, Bianchini D, Bahl A, Srihari N, Di Costanzo F, Smalley B, Parkes J, Crabb S, Vasudev N, Poprach A, Brown N, James L, Haywood S, Tapia J, Vijay A, Parry J, Cheung M, Mahajan I, Moon NO, Abrol R, Tkadlecová M, Yee Soe YS, Zargham A, Smith M, Ashley S, Hardy O, Patel G, Tun KK, Johnston E, Sarwer A, Bölek H, Shrestha R, Challapalli A, Meegan J, Anpalakhan S, Buono F, Kolarikova E, Leung DK, Murianni V, Catalano F, Bimbatti D, Buti S, Signori A, Fornarini G, Rescigno P, Chun Teoh JY, Banna GL.
Rebuzzi SE, et al. Among authors: bahl a.
Oncologist. 2026 May 20:oyag203. doi: 10.1093/oncolo/oyag203. Online ahead of print.
Oncologist. 2026.
PMID: 42159577
Free article.